Biotech firm Mnemo Therapeutics announces launch of RHU program
Category: #health  By Pankaj Singh  Date: 2022-06-13
 | 
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

Biotech firm Mnemo Therapeutics announces launch of RHU program

Biotechnology company Mnemo Therapeutics has reportedly kicked off its participation in the Hospital-University RHU (Research in Health) program.

Designed by the National Research Agency of France, the RHU funding underpins cross-institutional collaborations and advanced research. This consolidates businesses, academia, and hospitals to explore the possibilities in healthcare.

In December last year, nearly 17 proposals were chosen for the RHU funding and the EpCART project is one among them.

Spearheaded by Sebastian Amigorena, Ph.D., one of the scientific co-founders of Mnemo, the project intends to clinically authenticate an advanced approach to CAR-T immunotherapy.

Mnemo CEO Robert LaCaze has stated that the company is honored to be awarded for this distinguished initiative alongside its long-standing collaborators at Institut Curie.

The EpCART project emphasizes CAR-T cell epigenetic reprogramming. By inactivating SUV39H1, a crucial enzyme in the T cell differentiation pathway, the cell memory phenotype can be increased substantially. This works to achieve long-term control of tumors, addressing patient relapse.

Over the next five years, this project will look to clinically authenticate this technology as an analogous therapy.

Mnemo will collaborate with other EpCART partners to perform a Phase-II trial, assessing the activity of these CAR-T therapies in a group of 35 patients with solid tumors that are difficult to treat.

The EpCART project will expedite research on the EnfiniT Discovery Engine, an integrated tool of drug discovery that combines major technologies to develop long-lasting immune therapy and recognize advanced cancer-specific targets.

For the uninitiated, Mnemo develops transformational immunotherapies to enhance the ability of the body to overcome cancer.

EnfiniT Discovery Engine is integral to Mnemo's approach and comprises major technologies that work to recognize advanced cancer-specific antigens and improve the persistence and memory of immune cells.

The company will harness these technologies with several modalities across a variety of oncological indications to transform the lives of cancer patients.

Source credit:

https://www.prnewswire.com/news-releases/mnemo-therapeutics-launches-rhu-project-in-collaboration-with-leading-european-research-partners-institut-curie-and-meary-cell-and-gene-therapy-center-ap-hp-301565129.html



About Author

Pankaj Singh

Email: [email protected]   linkdin twitter

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

More News By Pankaj Singh

Rona Therapeutics obtains global rights to Sanofi's siRNA platform

Rona Therapeutics obtains global rights to Sanofi's siRNA platform

By Pankaj Singh

Rona Therapeutics Inc has reportedly acquired the global exclusive rights to the siRNA platform of delivery moiety and chemical modification from Sanofi S.A., in addition to four pre-clinical contenders for unrevealed ...

Toy maker Mattel inks multi-year agreement with Elon Musk’s SpaceX

Toy maker Mattel inks multi-year agreement with Elon Musk’s SpaceX

By Pankaj Singh

California-based toy manufacturing and entertainment company, Mattel, has recently signed a multi-year agreement with Elon Musk’s private spaceflight company, SpaceX.

T...

USHV partners with Willowbrook to provide quality cardiovascular care

USHV partners with Willowbrook to provide quality cardiovascular care

By Pankaj Singh

US Heart & Vascular (USHV) is reportedly partnering with Willowbrook Cardiovascular Associates to offer quality cardiovascular care in the Houston market.

USHV has a strong ma...